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Abstract
Italy was the first European country to be hit by COVID-19 pandemic. As a consequence, Italian oncologists had to guar-
antee essential treatments although minimizing exposure to the virus, and accidental infection, of patients and healthcare 
professionals. As Department of Medical Oncology of the University Hospital of Udine, in this short report, we describe 
the measures that we have taken, and gradually updated, since February 26, 2020. All accesses to our Oncology facilities 
are currently regulated by entrance check-points where patients are screened for infections following dedicated algorithms. 
Up to date, after 6 weeks of systematic execution of swabs no physician, nurse or other individual of the staff has been found 
positive to COVID-19. Only one patient admitted for therapy has been identified as COVID-19 positive. The aim of our 
work is to propose a model, made up of a set of operative procedures, that may be adopted by all the oncologists that daily 
struggle to guarantee safety and care in Oncology during this COVID-19 emergency.
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Introduction
The city of Wuhan, in China, was hit by a novel coronavi-
rus called SARS-CoV2 by December 2019, causing a novel 
acute respiratory disease known as COVID-19 [1]. Soon it 
was made clear that the possible origin of this virus could 
be the seafood and animal market of the town, in Hubei 
province, China [2, 3]. As a consequence of this outbreak, an 
aggressive policy of isolation of individuals was pursued by 
the Chinese Government. Soon it was clear that COVID-19 
would have become a Pandemic as it reached the status of a 
new disease spreading rapidly worldwide in a sustained fash-
ion (declaration of pandemic by the World Health Organiza-
tion was released on March 11, 2020). Italy was recognized 
to be the first country in Europe to face an outbreak of the 
virus, and it was also the first European country to put into 
practice measures of “social distancing” and “home quar-
antine” of affected patients first until the moment when it 
became obvious that the same restrictions were to be applied 
to every Italian citizen so that by the 9th of March the Italian 
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Prime Minister, in accordance with an emergency scientific 
task force, decided to “lockdown” the entire Country. On 
the field of Public Healthcare, Italy faced an unprecedented 
need to reconvert almost all elective clinical activities (i.e., 
non-urgent surgery and programmed ambulatory visits) 
into emergency and intensive care unit medical practice. To 
the date of 7th April, Italy registered 135,586 total cases 
of COVID-19, 94,067 positive individuals and more than 
17,127 deaths, as reported by the Italian “Istituto Superiore 
di Sanità” [4]. Italian medical Oncologists were among the 
first professionals to decide how to guarantee essential treat-
ments thus minimizing exposure and accidental infection of 
patients and healthcare professionals by SARS-CoV2 [5, 6]. 
In fact, oncology patients represent a particularly vulnerable 
category exposed to immune depression often caused by 
anticancer treatment as well as by the underling disease [7]. 
On the one hand, this represents the greatest risk factor for 
fatal outcome by the infection operated by this SARS Coro-
navirus but, on the other, healthcare professionals involved 
in cancer care could be easily exposed to this chain of trans-
mission due to, both, infections propagated by vulnerable 
patients and continuous incubation made by asymptomatic 
physician and nurses from oncology. Recently, the Italian 
Association for Medical Oncology (AIOM) has produced 
recommendation about how to cope with oncology clinical 
activity during the persistent emergency caused by COVID-
19, followed by the European Society for Medical Oncology 
[5]. It is thus important to somehow prioritize processes in 
oncology [8]. A group of young Italian oncologists have pro-
posed some general procedures to manage oncology activity 
in the era of this pandemic differentiating three main set-
tings: follow-up management, active treatment decisions and 
hospital admission workup [7]. As Department of Oncology 
of the University Hospital of Udine, in the North-Eastern 
Italian Region of Friuli Venezia Giulia, we manage about 
1600 first consultations and 10,000 drug administration ses-
sions per year, 50–60 patients who daily access Day Hospital 
(DH, the facility dedicated to cancer treatment sessions) and 
40–50 other accessing to Outpatient Clinics (facility where 
first visits and re-assessments take place). Our group was 
actively involved, by the very beginning of this emergency, 
in designing local procedures integrating the indications 
made by the Italian and regional Government. Indeed, our 
Hub Academic Hospital serves most of the cancer care of a 
region accounting for about 1,200,000 inhabitants.
The Friuli Venezia Giulia was, as well, one of the first 
Italian Regions to adopt the most stringent rules for con-
taining the spread of the viral outbreak started in the near 
Lombardia and Veneto.
In this short report, we describe the measures that we 
have taken, and gradually updated, since February 26, 2020. 
We also give a report of the first results regarding patients 
and staff surveillance.
In order to ensure the continuum of care and organize 
the protective measures needed for COVID-19, four main 
questions have to be answered: how to provide access and 
protection to patients, how to re-organize the activities, how 
to protect healthcare workers, how to manage the ongoing 
clinical trials.
Access to the facilities and patient 
protection
Day hospital
• All the patients accessing the DH must be negative to 
a structured triage carried out by trained staff (nurse or 
social assistance operator) through an interview, a self-
certification module (attached document 1) and the body 
temperature detection. In case of doubtful or positive tri-
age, an assessment by the doctor on duty is required. The 
access follows the procedures shared with the Hematol-
ogy Department, due to some common spaces of DH 
(reception area, waiting room): see Algorithm 1 (attached 
document 1). Patients resulting negative from the triage 
proceed to the DH wearing surgical mask, following an 
accurate hand washing and keeping social distance.
• To guarantee the minimal possible amount of individ-
uals accessing the DH, the companions’ access is not 
allowed (only exception for non-autonomous patients). 
The administration area, the blood-drawing area and the 
outside waiting rooms are forbidden to the companions. 
In the event the access of a companion is needed (max 1 
person), he/she must fill out the self-certification module 
and must be negative to the triage; to access the DH it 
is compulsory to wear the surgical mask and carry out 
hands’ hygiene.
• In case of positive triage, the oncologist on duty follows 
the procedures indicated in Algorithm 2.
• The oncologists operating the treatment visits assess the 
biological characteristics of the tumor, patient’s clinical 
scenario, the prognosis in relation to potential health 
risks from SARS-CoV2 infection and define the cases 
for which it is possible to postpone the treatment or re-
modulate its intensity. The following accesses are re-
scheduled (when necessary, by sharing the case with the 
reference medical doctor). In the case of re-scheduling 
in absence of the patient, the latter will be notified by the 
executive medical doctors or by the DH secretary.
• Clinical information about DH patients to previously 
authorized relatives are mainly provided by telephone 
or, in selected cases, in a fashion like the one used in the 
Ward Area (using external spaces).
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Outpatient clinics
• All the patients accessing the Outpatient Clinics must 
result negative to the structured triage carried out by 
the secretary staff (behind a glass barrier) thorough 
an interview and a self-certification module, following 
shared procedures (Algorithms 1 and 2). In case of a 
positive triage, the oncologist on duty assesses the case 
following the procedures in Algorithm 2. In the case of 
doubtful triage, the secretary staff requests assessment 
by an oncologist. Patients with negative triage proceed 
to the Clinics wearing a surgical mask and following 
an accurate hand washing.
• To guarantee the minimal possible amount of individu-
als entering the Clinics, the access of companions is not 
allowed (only exception for non-autonomous patients) 
to secretary staff area, to external waiting rooms and to 
the clinics as well. In the event the access of a compan-
ion is needed (max 1 person), he/she must fill out the 
self-certification module and must be negative to the 
triage procedure; to access the Clinics, it is compulsory 
to wear the surgical mask and carry out hands’ hygiene.
• Follow-up visits (i.e., visit of patients cured from cancer) 
are suspended, while the activity concerning first vis-
its, priority visits and reassessment visits are operating, 
except for some cases at the discretion of the executive 
medical doctors (see “reorganization of clinic activities” 
chapter).
Ward area
• All the patients accessing the integrated oncology-radi-
otherapy and palliative care Ward upon a programmed 
admission must perform a SARS-CoV2 swab within 
24–48 h preceding the hospitalization and it must result 
negative before the patient is admitted.
• Specifically, in case of programmed admission for ther-
apy, a SARS-CoV2 swab and a pre-therapy blood draw 
are performed by a dedicated nurse (wearing adequate 
personal protection), in DH, followed by clinical assess-
Algorithm  1  Instruction for DH triage. The nurse or social assis-
tance operator standing outside the DH is dedicated to the triage. This 
staff follows the conduct described in the diagram after administer-
ing the self-certification module (attachment 1) and after evaluating 
the answers. The algorithm provides the measures to be put into place 
upon a negative or positive triage
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ment by the medical doctor on duty who produces a 
“Visit for therapy” and fills out the workup. The dedi-
cated room lies isolated from the rest of DH. The patient 
returns then back home. The exams and swab results are 
assessed form the oncologist of the Ward, who makes 
a telephone call to the patient and confirms/postpones 
the hospitalization, validates the therapy and shares the 
decision with the nurse in the hospitalization area.
• The patient transferred to the Ward from another facility 
(or form the Emergency ER) or from another hospital 
can access only in case of recent negative swab (within 
max 48 h) to be executed even in the absence of specific 
symptoms.
• The patient discharged to external Facilities (e.g., Nurs-
ing home, Residences, Hospice, or other Hospitals) must 
result negative to the swab within the 48 h preceding the 
release.
• The repetition of swabs for recovered and isolated 
patients are carried out following the Clinical Risk Man-
agement Unit procedures or at the discretion of the con-
sultant oncologist responsible for the Ward, to patients 
with COVID-19 suspicious symptoms and/or in case of 
the presence of positive swabs from other patients and/
or from the staff operating in the Ward.
• As a rule, visits from relatives are not allowed, except 
for cases regulated by the charge nurse or by the medi-
cal doctor responsible for the Ward, after the assessment 
of the specific case. The authorized patients must not 
show any respiratory symptom, wear the surgical mask 
and carry out hands’ hygiene. Relatives with respiratory 
symptoms are not allowed for visits in any case.
• Information for families (or other care-givers) author-
ized by the patient are provided by the oncologist by 
telephone call. In the case “in-person conversation” is 
clearly needed, it must be carried out outside the Ward, 
preferably with one person only; both the medical doctor 
who provides information and the interlocutor must wear 
the surgical mask.
• Students, medical residents, voluntary organization rep-
resentatives and other attendees are not allowed.
• All the inquiries and non-essential or non-urgent proce-
dures for the therapy programs that involve the transfer 
Algorithm 2  Instruction for medical and nursing staff upon positive 
triage. In case of positive triage (see attachment 1), the staff follows 
the conduct described in this diagram. Three main scenarios and their 
management are represented: patient with mild symptoms without 
known contact to COVID-19-positive subjects, patient with no symp-
tom but had known contact with COVID-19-positive subject, patient 
with non-mild symptoms or mild symptoms with known contact with 
COVID-19-positive subject
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of the patient outside the ward must be reconsidered and 
possibly postponed; if confirmed, the patient will exit the 
Ward wearing the surgical mask.
Reorganization of clinical activities
• Follow-up visits: Suspended. The Secretary staff noti-
fies to patients with programmed follow-up visits not to 
attend them in the hospital and informs that they will 
be called by telephone by the doctor, normally on the 
same day the visit was scheduled. The secretary accepts 
patients on the scheduled day with the “remote visit” pro-
vision. At the end of the telephone interview, the treat-
ment report is produced and sent to the patient, together 
with the referrals (prescriptions) for the following exams: 
the documentation sent by e-mail should be zipped and 
encrypted when possible or sent by mail service (by the 
Secretary) when necessary. This procedure is applicable 
to patients affected by the most prevalent cancer types 
that are usually cured with surgery or after adjuvant 
chemotherapy (i.e., mostly breast cancers, colorectal 
cancers and other gastro-intestinal cancers). Visits are 
otherwise shortly reprogrammed in case of symptoms 
or examinations that may result suspect for recurrence 
of disease after the telephone consultation.
• First consultations, priority and reassessment visits: regu-
larly going on, except for visits deemed deferrable by the 
executive oncologist (e.g., reassessment visit with stable 
disease on radiological report and stable clinical condi-
tion or first consultation when histological exam is not 
yet available).
• Therapy visits: to limit accesses, the oncologists assess 
the biological characteristics of the tumor, patient’s 
clinical scenario, the prognosis in relation to potential 
health risks from COVID-19 infection and define the 
cases for which it is possible to postpone the treatment 
or re-modulate its intensity. Re-scheduling is especially 
considered for patient in advanced treatment lines for 
which very limited efficacy is expected by the treatment. 
Maximal priority is instead guaranteed for treatments of 
proven high probability of efficacy or for adjuvant treat-
ments in a curative setting. The following accesses are 
re-scheduled by short, medium or long term according to 
the necessity (when needed, by sharing the case with the 
reference oncologist). Reference oncologist, regardless 
the shifts, re-examine whenever possible the program of 
the patients under their responsibility, canceling or post-
poning, whenever possible, the unnecessary visits.
• Multidisciplinary activities and facility clinical meeting: 
suspended. Possible clinical situations requiring multi-
disciplinary discussion are debated among medical doc-
tors from different Facilities by telephone or by physical 
meeting only in case rules of social safety distance and 
protection equipment adequacy are respected. Multi-
professional meetings are held in Ward area with these 
measures.
• Consultancies: whenever possible and for limited con-
texts, the Consulting activities provided by Department 
of Oncology or medical advices requested by other Units 
are fulfilled by telephone or by remote to limit the move-
ments/flows of patients and medical personnel within dif-
ferent assistance facilities.
• Urgent visits and non-programmed accesses: regularly 
continuing. Patients with issues related to treatment tox-
icities or to the management of severe symptoms related 
to cancer are included in this category. Patients are sub-
mitted to triage and body temperature detection before 
accessing. In the event of doubtful or suspicious cases, 
Algorithm 2 procedures are triggered.
Personnel protection
• All medical doctors and personnel operating in the 
Oncology Department are submitted, starting from 
18.3.20 to SARS-CoV2 basal swab and periodically re-
assessed (every week for two weeks, then every 2 weeks).
• All medical doctors and personnel operating in the 
Oncology Department who refer temperature or symp-
toms associated with infection should promptly commu-
nicate it to the Director of the Department and then be 
evaluated by the infectious risk management Hospital 
task force.
• Medical doctors visit with surgical mask and disposable 
gloves. Additional protections are adopted according to 
case by case risk assessment, as indicated by Risk Man-
agement Unit of our Hospital.
• Each medical doctor and operator in the area takes care 
of his/her own workplace and integrates the daily sani-
tization (already foreseen) in the common workplace 
areas. Daily work uniform change is recommended to 
each medical doctor and operator.
Research activities
The suspension of recruitment activities is recommended, 
except for selected interventional studies (potential benefit 
assessed case by case). The monitoring of clinical studies, 
when non-deferrable, must be carried out by remote. For 
the patients already on treatment within the scope of clini-
cal study, it is recommendable to substitute the activities 
foreseen by procedures, whenever possible, with contact by 
telephone (e.g., lifestyle surveys, safety visits).
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Other indications
• Avoid gatherings as far as possible. It is necessary to 
maintain the social distancing and avoid contacts with 
other operators.
• Except for “doctor on call duties” and strict necessities, 
avoid as far as possible interactions among people from 
different teams (ward team, clinic team, DH team).
• Keep tidy and clean (sanitizing) workplaces before and 
after every use (including mouse, keyboards, telephone 
handset, handles, etc.).
• Frequently aerate, whenever possible, used premises.
• As usual, it is recommended not to wear necklaces nor 
jewelry.
• Possible not-deferrable meetings must be carried out with 
the strictly needed amount of people in premises com-
patibles with social distancing.
Up to date, after 6 weeks of systematic execution of 
swabs (one test for each operator, every week for two weeks 
for all the 91 people daily operating in our Oncology), no 
physician, nurse or other individual of the staff has been 
found positive to SARS-CoV2 in the three articulations of 
our Department (after 1116 total swabs). Only one patient 
admitted for therapy has been identified SARS-CoV2 posi-
tive, but 9 days after accessing and in a home setting; the 
controls on contacts with the health personnel resulted nega-
tive. From March 6, 2020, swabs are performed to every 
patient entering DH for a therapeutic infusion at least 30 min 
long.
In conclusion, we strongly believe that all these pruden-
tial measures, which have been adopted since February 26, 
2020 and gradually updated in our Oncology Department, 
together with the Hematology Department, could serve as a 
model to be replicated. In the perspective of the next months, 
it will be crucial to maintain this same prudential attitude 
towards prevention of infection by SARS-CoV2, even after 
the re-opening of social activities, given the possibility that 
this virus will be further circulating exploiting asymptomatic 
subjects as carriers. Finally, this emergency could serve as 
a turning point for re-considering measures of protection of 
cancer patients from infectious risks as well as for learning 
the lesson of prioritizing the treatments. We hope that our 
complex organizing strain will be of utmost help to all the 
oncologists that, around the world, need to carry out the 
defense of all the vulnerable cancer patients and guarantee 
the preservation of the precious health of our colleagues.
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